SANOFI ADR

NASDAQ: SNY (Sanofi)

Kemas kini terakhir: 16 jam lalu

49.53

0.63 (1.29%)

  • 1H 1.29%
  • 5H -0.70%
  • 1B -2.23%
  • 6B -0.44%
  • Tahun Ke Tarikh 2.78%
  • 1T 2.27%
  • 5T -0.20%
Penutupan Terdahulu 48.90
Buka 49.71
Jumlah Dagangan 2,342,411
Purata Dagangan (3B) 2,918,939
Modal Pasaran 120,898,920,448
Harga / Pendapatan (P/E TTM) 16.24
Harga / Pendapatan (P/E Ke hadapan) 9.97
Harga / Jualan (P/S) 2.28
Harga / Buku (P/B) 1.41
Julat 52 Minggu
44.62 (-9%) — 60.12 (21%)
Tarikh Pendapatan 29 Jan 2026
Hasil Dividen (DY TTM) 4.47%
Margin Keuntungan 13.95%
Margin Operasi (TTM) 20.78%
EPS Cair (TTM) 2.94
Pertumbuhan Hasil Suku Tahunan (YOY) -4.60%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 65.20%
Jumlah Hutang/Ekuiti (D/E MRQ) 23.01%
Nisbah Semasa (MRQ) 1.46
Aliran Tunai Operasi (OCF TTM) 9.08 B
Aliran Tunai Bebas Leveraj (LFCF TTM) -4.94 B
Pulangan Atas Aset (ROA TTM) 4.28%
Pulangan Atas Ekuiti (ROE TTM) 7.30%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menurun
Drug Manufacturers - General (Global) Menaik Menurun
Stok Sanofi Menurun Menurun

AISkor Stockmoo

-0.5
Konsensus Penganalisis -0.5
Aktiviti Orang Dalam NA
Volatiliti Harga -1.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal -0.5
Purata -0.50

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
SNY 121 B 4.47% 16.24 1.41
AZN 282 B 1.72% 30.18 6.09
AMGN 182 B 2.82% 26.13 19.34
GILD 154 B 2.55% 19.24 7.32
GRFS 7 B 1.96% 14.05 1.00
BIIB 27 B - 16.61 1.42

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Core
% Dimiliki oleh Institusi 10.49%

Pemilikan

Nama Tarikh Syer Dipegang
Mondrian Investment Partners Ltd 30 Sep 2025 3,638,606
Julat 52 Minggu
44.62 (-9%) — 60.12 (21%)
Median 58.00 (17.10%)
Jumlah 1 Beli
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Morgan Stanley 08 Sep 2025 58.00 (17.10%) Beli 46.80

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
04 Dec 2025 Pengumuman Press Release: Sanofi completes acquisition of Vicebio
04 Dec 2025 Pengumuman Press Release: Sanofi completes acquisition of Vicebio
25 Nov 2025 Pengumuman Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
25 Nov 2025 Pengumuman Press Release: Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria
18 Nov 2025 Pengumuman Lifordi Immunotherapeutics Secures Strategic Investment from Sanofi Ventures and Additional Capital from Existing Investors
14 Nov 2025 Pengumuman Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
14 Nov 2025 Pengumuman Press Release: Sanofi’s Teizeild recommended for EU approval by the CHMP for patients with stage 2 type 1 diabetes
13 Nov 2025 Pengumuman Sanofi: Information concerning the total number of voting rights and shares – October 2025
07 Nov 2025 Pengumuman Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
07 Nov 2025 Pengumuman Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review
28 Oct 2025 Pengumuman Press release: Sanofi successfully prices USD 3 billion of bond issue
28 Oct 2025 Pengumuman Press release: Sanofi successfully prices USD 3 billion of bond issue
27 Oct 2025 Pengumuman UPDATE - Medidata Extends Collaboration with Sanofi for the Development of New Therapies with an Improved Patient Journey
24 Oct 2025 Pengumuman Press release: Q3: continued sales and earnings progress
24 Oct 2025 Pengumuman Press release: Q3: continued sales and earnings progress
23 Oct 2025 Pengumuman Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey
22 Oct 2025 Pengumuman Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
22 Oct 2025 Pengumuman Press Release: Sanofi’s efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study
20 Oct 2025 Pengumuman Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
20 Oct 2025 Pengumuman Press Release: Sanofi’s Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program
20 Oct 2025 Pengumuman Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
20 Oct 2025 Pengumuman Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
20 Oct 2025 Pengumuman Press Release: ESMO: AlphaMedixTM phase 2 data support first-in-class potential of new targeted alpha therapy in gastroenteropancreatic neuroendocrine tumors
20 Oct 2025 Pengumuman Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
20 Oct 2025 Pengumuman Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
17 Oct 2025 Pengumuman Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
17 Oct 2025 Pengumuman Press Release: Sanofi provides update on regulatory review in the EU for Rezurock to treat chronic graft-vs-host disease
17 Oct 2025 Pengumuman Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
17 Oct 2025 Pengumuman Press Release: Sanofi’s Wayrilz recommended for EU approval by the CHMP to treat immune thrombocytopenia
16 Oct 2025 Pengumuman EVOQ Therapeutics Announces Collaboration and License Agreement with Sanofi
14 Oct 2025 Pengumuman Sanofi: Information concerning the total number of voting rights and shares - September 2025
08 Oct 2025 Pengumuman Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
08 Oct 2025 Pengumuman Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
08 Oct 2025 Pengumuman Press Release: AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in patients with gastroenteropancreatic neuroendocrine tumors
02 Oct 2025 Pengumuman Revvity Announces Program to Revolutionize the Early Detection of Type 1 Diabetes
26 Sep 2025 Pengumuman Sanofi expands patient affordability program by offering access to all its insulins for $35 per month in the US
24 Sep 2025 Pengumuman Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
24 Sep 2025 Pengumuman Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation
24 Sep 2025 Pengumuman Press release: Availability of the Q3 2025 Aide mémoire
24 Sep 2025 Pengumuman Press release: Availability of the Q3 2025 Aide mémoire
23 Sep 2025 Pengumuman Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
23 Sep 2025 Pengumuman Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1
22 Sep 2025 Pengumuman Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
22 Sep 2025 Pengumuman Press Release: Update on the US regulatory review of tolebrutinib in non-relapsing, secondary progressive multiple sclerosis
22 Sep 2025 Pengumuman Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
22 Sep 2025 Pengumuman Press Release: Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
17 Sep 2025 Pengumuman Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
17 Sep 2025 Pengumuman Press Release: EADV: Sanofi’s brivekimig achieved positive results in hidradenitis suppurativa in phase 2a study
12 Sep 2025 Pengumuman Sanofi: Information concerning the total number of voting rights and shares - August 2025
11 Sep 2025 Pengumuman Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
11 Sep 2025 Pengumuman Press Release: Sanofi’s SAR402663 earns fast track designation in the US for neovascular age-related macular degeneration
10 Sep 2025 Pengumuman Mandy Moore and Celebrity Mom Squad join Sanofi to help protect babies from RSV with BEYFORTUS®
10 Sep 2025 Pengumuman Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
10 Sep 2025 Pengumuman Press Release: Tzield approved in China as first disease-modifying therapy for adult and pediatric patients with stage 2 type 1 diabetes
Papar semua
Hasil Dividen (DY TTM) 4.47%
Purata Hasil Dividen 5T 4.78%
Nisbah Pembayaran 75.37%
Jangkaan Pembayaran Dividen Seterusnya Jun 2026
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
09 May 2025 15 Apr 2025 12 Jun 2025 2.212154 Tunai
09 May 2024 26 Mar 2024 06 Jun 2024 2.037356 Tunai
09 May 2024 26 Mar 2024 06 Jun 2024 2.0369079 Tunai
30 May 2023 - 23 Jun 2023 1.9000852 Tunai
26 May 2022 - 27 Jun 2022 0.2971788 Tunai
04 May 2022 20 Apr 2022 31 May 2022 1.7967514 Tunai
03 May 2021 23 Mar 2021 26 May 2021 1.906064 Tunai
30 Apr 2020 05 Mar 2020 26 May 2020 1.6993994 Tunai
07 May 2019 - 31 May 2019 1.722322 Tunai
09 May 2018 07 Feb 2018 04 Jun 2018 1.860874 Tunai
11 May 2017 16 Feb 2017 07 Jun 2017 1.577088 Tunai
05 May 2016 19 Feb 2016 01 Jun 2016 1.630252 Tunai
06 May 2015 25 Feb 2015 02 Jun 2015 1.618087 Tunai
17 May 2010 12 Feb 2010 14 Jun 2010 1.62732 Tunai
04 Jun 2007 05 Mar 2007 03 Jul 2007 1.14537 Tunai
02 Jun 2006 06 Mar 2006 03 Jul 2006 0.912 Tunai
02 Jun 2005 01 Mar 2005 01 Jul 2005 0.7993 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2025 2.21 1 4.47
2024 4.07 2 8.45
2023 1.90 1 3.82
2022 2.09 2 4.32
2021 1.91 1 3.81
2020 1.70 1 3.50
2019 1.72 1 3.43
2018 1.86 1 4.29
2017 1.58 1 3.67
2016 1.63 1 4.03
2015 1.62 1 3.79
2010 1.63 1 5.05
2007 1.15 1 2.52
2006 0.912 1 1.98
2005 0.799 1 1.82
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda